Optical imaging of primary and regional melanoma to guide surgical resection
Optical imaging of primary and regional melanoma to guide surgical resection
批准号:
8564734
负责人:
EBEN L. ROSENTHAL
金额:
$19.17万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-10 至 2015-06-30
关键词:
AddressAntibodiesAntigensBedsBlood VesselsClinicalContrast MediaDetectionDiseaseDoseDyesEpidermal Growth Factor ReceptorEquipmentExcisionFDA approvedFailureFluorescenceFrozen SectionsHistologyHumanImageIn VitroIncidenceLabelLymphaticMalignant NeoplasmsMethodsMicroscopicModalityModelingMolecularMusNeoplasm MetastasisNormal tissue morphologyOperative Surgical ProceduresOpticsOutcomeParaffin EmbeddingPenetrationPhysiologicalPreclinical TestingPredictive FactorPrimary NeoplasmProceduresProcessRegional DiseaseSampling ErrorsSensitivity and SpecificitySkinSkin CarcinomaSkin graftSurgeonSurgical OncologySurgical marginsTechniquesThickTimeTissuesToxic effectTranslationsTumor AntigensVascular PermeabilitiesXenograft procedurebasebevacizumabcancer imagingcancer surgerycancer typeimprovedin vivointraoperative imagingintravenous administrationmelanomamortalitynoveloptical imagingpanitumumabpublic health relevancereconstructiontumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Primary treatment for melanoma remains surgical excision with negative margins. Unfortunately, melanoma margins cannot be visualized or palpated; as a result surgeons obtain wide margins of healthy appearing tissue based on tumor histology and depth of penetration. Failure to improve surgical cures contributes to a failure to improve survival in this disease while most other cancer types have shown dramatically improved survival over the same time period. Improving melanoma survival depends on improving the primary treatment modality. We propose to determine if FDA approved antibodies to commonly expressed melanoma antigens can be leveraged for imaging of microscopic margins and regional disease. We propose to identify the optimal antibody (or combinations) for imaging, the sensitivity and specificity of this technique and the mechanisms by which it promotes fluorescence in the tumor. Using this strategy, histological margins can be selectively obtained and normal tissues spared. If successful such a technique would dramatically impact how surgical resections are performed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
American Head and Neck International Conference
-
批准号:10753698
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2023
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer
-
批准号:10671612
-
项目类别:
-
资助金额:$45.27万
-
财政年份:2022
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer
-
批准号:10508399
-
项目类别:
-
资助金额:$42.6万
-
财政年份:2022
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Next Generation Sentinel Node Mapping
-
批准号:10532064
-
项目类别:
-
资助金额:$4.91万
-
财政年份:2019
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)
-
批准号:9586709
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2018
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)
-
批准号:10496780
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2018
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)
-
批准号:9727786
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2018
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)
-
批准号:10164616
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2018
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Prototype optical device for image guided surgery with panitumumab-IRDye800
-
批准号:8969649
-
项目类别:
-
资助金额:$49.27万
-
财政年份:2015
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Prototype optical device for image guided surgery with panitumumab-IRDye800
-
批准号:9342705
-
项目类别:
-
资助金额:$58.5万
-
财政年份:2015
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Prototype optical device for image guided surgery with panitumumab-IRDye800
-
批准号:9759821
-
项目类别:
-
资助金额:$42.01万
-
财政年份:2015
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Imaging Guided Surgery using Fluorescently Labeled Cetuximab
-
批准号:8765574
-
项目类别:
-
资助金额:$26.81万
-
财政年份:2014
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Optical imaging of primary and regional melanoma to guide surgical resection
-
批准号:8699170
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2013
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
8th Annual Conference on Head and Neck Cancer
-
批准号:8319118
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2012
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
CD147 as a Novel Target in Head and Neck Cancer
-
批准号:8444266
-
项目类别:
-
资助金额:$24.95万
-
财政年份:2010
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
CD147 as a Novel Target in Head and Neck Cancer
-
批准号:8621981
-
项目类别:
-
资助金额:$25.74万
-
财政年份:2010
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
CD147 as a Novel Target in Head and Neck Cancer
-
批准号:8024535
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2010
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
CD147 as a Novel Target in Head and Neck Cancer
-
批准号:8225379
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2010
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
CD147 as a Novel Target in Head and Neck Cancer
-
批准号:7899557
-
项目类别:
-
资助金额:$27.36万
-
财政年份:2010
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
Fluorescently Labeled Anti-EGFR to Guide Removal of Lymph Node Metastasis
-
批准号:7738795
-
项目类别:
-
资助金额:$18.3万
-
财政年份:2009
-
负责人:EBEN L. ROSENTHAL
-
依托单位:
海外基金